1. Introduction {#sec1}
===============

There were many controversies about postoperative radiotherapy (PORT) in IIIA non-small-cell lung cancer (NSCLC) patients with pathologically confirmed N2. For one thing, local recurrence and distant metastasis were the main reasons for treatment failure of PORT in stage IIIA-N2 NSCLC patients, as the local recurrence rate and distant metastasis rate were 23%\~33% and more than 50%, respectively \[[@B1]\]. Furthermore, stage IIIA-N2 NSCLC patients had increased local control rates and decreased recurrence rates after surgery. However, as for survival rate, different researchers have different conclusions \[[@B2]--[@B4]\]. To analyze reasons for the different conclusions, one reason may be a slight difference in the standard of tumor staging in different periods. Another reason may be using different treatment models in different periods, while a third reason may be due to development stage of the radiotherapy techniques used.

Since the 1990s, radiotherapy techniques developed from two-dimensional techniques to three-dimensional precise radiotherapy techniques gradually. The three-dimensional precise radiotherapy techniques mainly contain conformal radiation therapy (CRT) and intensity modulated radiation therapy (IMRT). The IMRT has fix field IMRT, volumetric modulated arc therapy (VMAT, hereinafter referred to as ARC), and helical tomotherapy (HT). The CRT, IMRT, and ARC have been used widely in most hospitals in China and each has technical advantages of their own. The CRT is relatively safe and stable with higher marginal dose of tumor while IMRT has good conformability and uniformity. However, the VMAT not only has good conformability and uniformity, but also faster treatment efficiency and fewer machine units.

The studies about PORT in stage IIIA-N2 NSCLC patients in the past have all adopted two-dimensional techniques and/or CRT techniques and seldom IMRT or VMAT techniques. In this study, we intended to compare the dosimetric characteristics of CRT, IMRT, ARC, CRT+IMRT, and CRT+ARC of PORT in stage IIIA-N2 NSCLC patients. We hoped that our study results would provide evidence for the clinical application of above techniques.

2. Materials and Methods {#sec2}
========================

2.1. Patients Selection and General Information {#sec2.1}
-----------------------------------------------

Ten patients with stage IIIA-N2 completely resected NSCLC, treated by PORT in radiotherapy department of our hospital from January 1, 2017, to January 1, 2018, were randomly selected in this study. There were 3 women and 7 men, aged 51\~69 years, with a median age of 65 years. Planning Target Volume (PTV) was 178.2\~430.8cc. The general clinical data of patients is shown in [Table 1](#tab1){ref-type="table"}.

2.2. Position Immobilized and CT Scans {#sec2.2}
--------------------------------------

Patients were lying on a CT bed in supine position and immobilized using thermoplastic masks. The Ge Corp CT scanner was used to simulate the positioning. The scanning thickness and spacing were both 2.5 mm. The CT images were transmitted to the ARIA server via the Varian ARIA oncology management software. Then images were received to local at treatment planning system (TPS) terminal.

2.3. Delineation of Targets and Organs at Risk (OARs) {#sec2.3}
-----------------------------------------------------

On TPS, targets and the OARs were delineated by a chief physician. According to the grouping and distribution criteria of mediastinal lymph nodes proposed by IASCLC in 2009, as for left NSCLC after complete resection, the targets included bronchial stump, 2R, 2L, 4R, 4L, 5, 6, 7, 10L, and 11L lymph nodes. As for right NSCLC after complete resection, the targets included bronchial stump, 2R, 4R, 7, 10R, and 11R lymph nodes. The OARs included spinal cord, esophagus, heart and double lung.

2.4. Treatment Plans Design {#sec2.4}
---------------------------

The plans were designed by a senior physicist in Varian Corporation Eclipse TPS (Eclipse version 10.0, Varian Medical Systems, Palo Alto, CA). For each patient, five plans were designed on the same set of CT images. 6 MV X-ray was selected, and the location of the field centers was the same. The first plan was CRT plan. Five fields were chosen for the CRT plan. The angle of fields depended on the location of tumors and followed the principle of "design fields near tumors". Conformity and homogeneity of targets were improved by adjusting fields\' weight and "field in field" techniques and avoided "hot points" and "cold points" at the same time. The second plan was IMRT plan. Five fields were also chosen for the IMRT plan and field angles were as same as the CRT plan. By setting appropriate optimization conditions and repeatedly optimizing, a plan meeting the clinical requirements was finally obtained. The third plan was ARC plan. There were two partial arcs for the ARC plan and arc positions were near tumors. The angle of collimator was 10° and 350°, respectively. The optimization conditions were the same as the IMRT plan and a plan meeting clinical requirements was finally obtained by repeated optimization.

The fourth plan was CRT+IMRT plan. Two opposing fields were chosen for the CRT plan and three fields for the IMRT plan. The three fields of IMRT plan distributed nearly as equal angle in the ipsilateral lung. Then the IMRT plan optimized based on the CRT plan, the optimization conditions were as same as the ARC plan and a plan meeting the clinical requirements was finally obtained by repeated optimization. The fifth plan was CRT+ARC plan. The CRT was the same as the CRT+IMRT plan. One partial arc was chosen for the ARC plan and optimized based on the CRT plan. The angle of collimator was 10° or 350°. The optimization conditions were the same as the CRT+IMRT plan and a plan meeting clinical requirements was finally obtained by repeated optimization.

Dose calculation of all plans was performed using analytical anisotropic algorithm (AAA). The prescription of five plans for the same patient was the same as 50 Gy, and the fraction dose was 2 Gy, a total of 25 times. The dose ratio of CRT and IMRT or ARC was 1:1. According to the NCCN guideline and related research results, the dose-limiting conditions were as follows: the prescription line encompassed over 95% of the target volume; the maximum dose of the spinal cord was less than 45 Gy; the V5 of the esophagus was less than 50%; the V30 and V40 of the heart were less than 40% and 30%, respectively; and the normal doses of normal lung volume V5, V20, and V30 were less than 60%, 25%, 20%, and 15 Gy, respectively.

2.5. Evaluation Methods {#sec2.5}
-----------------------

The isodose distribution and dose-volume histogram (DVH) of the five plans were compared to determine the dosimetric parameters of the targets, OARs, and the normal tissue (defined as Body subtracted to PTV, B-P). The targets were evaluated by the minimum dose, the maximum dose, the median dose, Homogeneity index (HI), Conformity index (CI), and the volume of the targets which were irradiated by higher than 105% prescription dose V105. HI and CI were calculated using the following equations:$$\begin{matrix}
{HI\operatorname{} = \frac{\left( {D_{2} - D_{98}} \right)}{D_{p}} \times 100\%;} \\
 \\
{CI\operatorname{} = \left( {\frac{V_{t,ref}}{V_{t}}} \right) \times \left( {\frac{V_{t,ref}}{V_{ref}}} \right)} \\
 \\
\end{matrix}$$*D*~2~ and *D*~98~ refer to the maximum dose encompassing 2% and 98% of PTV, respectively, *D*~*p*~ is the prescription dose. *V*~*t*~ is the volume of PTV, *V*~*t*,*ref*~ is the volume of PTV covered by reference isodose line, and *V*~*ref*~ is the volume of the body covered by reference isodose line.

The following parameters were used to evaluate the protection of OARs: the maximum dose of spinal cord; the V~50~ and maximum dose of esophagus; V~20~, V~30~, V~40~, V~45~, and average dose of heart; V~5~, V~13~, V~20~, V~30~, and average dose of double lung. The Vx here refers to the percentage of tissue exposed to X and Gy to the total volume. The percentage of B-P exposure to 5\~50 Gy volume and B-P volume, V~5\~50~. In addition, the number of machine units (MU) for the five plans was also evaluated.

3. Statistical Analysis {#sec3}
=======================

SPSS 22 software package was used for statistical description and analysis of the data. The paired t test was performed to test comparisons between two plans. A 2-tailed P-value of \< 0.05 was considered statistically significant.

4. Results {#sec4}
==========

4.1. CRT Plan versus IMRT Plan {#sec4.1}
------------------------------

As shown in [Table 2](#tab2){ref-type="table"}, the minimum dose of PTV in the CRT pan was better than the IMRT plan, and the difference was statistically significant, *t* = 6.698, *p* = 0.001. However, the Conformity index and V~105~ (%) of PTV in the CRT plan were worse than the IMRT plan, and the differences were statistically significant, *t* = −5.367, 2.359, *p* = 0.001, 0.043. The other dosimetric parameters of PTV in the CRT plan had no statistical differences compared with the IMRT plan.

As for OARs, V~50~ (%) of esophagus, V~30~ (%) of heart, and the mean dose of normal lung in the CRT plan had no statistical differences compared with the IMRT plan. The maximum dose of spinal cord in the CRT plan was higher than the IMRT plan, and the difference was statistically significant, *t* = 7.034, *p* = 0.001. The maximum dose of esophagus was lower than the IMRT plan, and the difference was statistically significant, *t* = −3.813, *p* = 0.004. The V~20~ (%), V~40~ (%), V~45~ (%), and mean dose of heart in the CRT plan were all higher than the IMRT plan, and the differences were statistically significant, *t* = 5.382, 2.864,2.832, 4.913, *p* = 0.001, 0.019,0.020, 0.001. The V~5~ (%), V~10~ (%), V~13~ (%), V~20~ (%), and V~30~ (%) of normal lung in the CRT plan were all higher than the IMRT plan, and the differences were statistically significant, *t* = 6.456, 2.653, 4.636,5.982,6.771, *p* = 0.001, 0.026, 0.001, 0.001, 0.001*;* see [Table 2](#tab2){ref-type="table"} for details.

As for B-P, the V~5\~50~ of B-P in the CRT plan were all higher than the IMRT plan, and the differences were not statistically significant for V~5~, V~25~, and V~30~, but the differences were statistically significant for V~10~, V~15~, V~20~, V~35~, V~40~, V~45~, V~50~,*t=2.347, 2.870, 2.363, 2.317, 3.181, 2.957, 2.771, p=0.044,0.018,0.042,0.046,0.011,0.016,0.022;*see [Table 2](#tab2){ref-type="table"} for details.

4.2. CRT Plan versus ARC Plan {#sec4.2}
-----------------------------

As shown in [Table 3](#tab3){ref-type="table"}, the median dose, the Conformity index, and V~105~ (%) of PTV in the CRT pan were worse than the ARC plan, and the differences were statistically significant,*t=-4.433, -15.148, 2.766, p=0.002, 0.001, 0.022.*The other dosimetric parameters of PTV in the CRT plan had no statistical differences compared with the ARC plan.

As for OARs, the maximum dose of spinal cord in the CRT plan was higher than the ARC plan, and the difference was statistically significant,*t=5.516, p=0.001.*The V~50~ (%) of esophagus was lower than the ARC plan, and the difference was statistically significant,*t=-4.286, p=0.002.* But the maximum dose of esophagus in the CRT plan had no statistical differences compared with the ARC plan. The V~20~ (%), V~30~ (%), V~40~ (%), V~45~ (%), and mean dose of heart in the CRT plan were all higher than the ARC plan, and the differences were statistically significant,*t=3.369, 2.393, 2.295, 2.278, 3.129, p=0.008, 0.040, 0.047, 0.049, 0.012.*The V~5~ (%), V~10~ (%), and mean dose of normal lung in the CRT plan had no statistical differences compared with the ARC plan. However, the V~13~ (%), V~20~ (%), and V~30~ (%) of normal lung in the CRT plan were all higher than the ARC plan, and the differences were statistically significant,*t=3.860, 4.551, 5.244, p=0.004, 0.001, 0.001;*see [Table 3](#tab3){ref-type="table"} for details.

As for B-P, the V~5\~50~ of B-P in the CRT plan were all higher than the ARC plan, and the differences were not statistically significant for V~5~, and V~10~, but the differences were statistically significant for V~15~, V~20~, V~30~, V~35~, V~40~, V~45~, V~50~,*t=4.121, 4.861, 4.142, 2.774, 2.532, 3.244, 2.999, 3.748, p=0.003, 0.001, 0.003, 0.022, 0.032, 0.010, 0.015, 0.005;*see [Table 3](#tab3){ref-type="table"} for details.

4.3. CRT Plan versus CRT+IMRT Plan {#sec4.3}
----------------------------------

As shown in [Table 4](#tab4){ref-type="table"}, the median dose and the Conformity index of PTV in the CRT pan were worse than the CRT+IMRT plan, and the differences were statistically significant,*t=-2.604, -7.910, p=0.001, 0.015.*The other dosimetric parameters of PTV in the CRT plan had no statistical differences compared with the IMRT plan.

As for OARs, the maximum dose of spinal cord in the CRT plan had no statistical difference compared with the CRT+IMRT plan. The maximum dose of esophagus was lower in the CRT plan than the CRT+IMRT plan, and the difference was statistically significant,*t=-2.739, p=0.023.* But the V~50~ (%) of esophagus in the CRT plan had no statistical difference compared with the CRT+IMRT plan. The V~20~ (%), V~40~ (%), V~45~ (%), and mean dose of heart in the CRT plan were all higher than the CRT+IMRT plan, and the differences were statistically significant,*t=3.369, 2.393, 2.295, 2.278, 3.129, p=0.008, 0.040, 0.047, 0.049, 0.012.*But the V~30~ (%) of heart in the CRT plan had no statistical difference compared with the CRT+IMRT plan. The V~5~ (%), V~10~ (%),V~13~ (%), and V~20~ (%) of normal lung in the CRT plan were all higher in the CRT+IMRT plan, and the differences were statistically significant,*t=5.435, 3.342, 5.082, 5.153, p=0.001, 0.009, 0.001, 0.001*. However, the mean dose and V~30~ (%) of normal lung in the CRT plan had no statistical differences compared with the CRT+IMRT plan*;*see [Table 4](#tab4){ref-type="table"} for details.

As for B-P, the V~5\~50~ of B-P in the CRT plan had no statistical differences compared with the CRT+IMRT plan*;*see [Table 4](#tab4){ref-type="table"} for details.

4.4. CRT Plan versus CRT+ARC Plan {#sec4.4}
---------------------------------

As shown in [Table 5](#tab5){ref-type="table"}, the median dose and the Conformity index of PTV in the CRT plan were worse than the CRT+ARC plan, and the differences were statistically significant,*t=-2.891, -12.227, p=0.001, 0.018.*The other dosimetric parameters of PTV in the CRT plan had no statistical differences compared with the CRT+ARC plan.

As for OARs, the maximum dose of spinal cord in the CRT plan had no statistical differences compared with the CRT+ARC plan. The maximum dose and the V~50~ (%) of esophagus in the CRT plan was lower than the CRT+ARC plan, and the differences were statistically significant,*t=-2.739, -2.911, p=0.023,0.017.* The V~20~ (%), V~40~ (%), and mean dose of heart in the CRT plan were all higher than the CRT+ARC plan, and the differences were statistically significant,*t=2.933, 2.310, 2.332, p=0.017, 0.046, 0.045*. But the V~30~ (%) of heart in the CRT plan was lower than the CRT+ARC plan, and the differences were statistically significant,*t=-3.529, p=0.006.*The V~45~ (%) of heart in the CRT plan had no statistical difference compared with the CRT+ARC plan. The V~5~ (%), V~10~ (%), V~13~ (%), V~20~ (%), and V20 (%) of normal lung in the CRT plan were all higher than the CRT+ARC plan, and the differences were statistically significant,*t=3.114, 6.330, 6.673, 6.319, 2.494, p=0.012, 0.001, 0.001, 0.001, 0.034*. However, the mean dose of normal lung in the CRT plan had no statistical differences compared with the CRT+ARC plan*;*see [Table 5](#tab5){ref-type="table"} for details.

As for B-P, the V~15~ and V~20~ of B-P in the CRT plan were higher than the CRT+ARC plan, and the differences were statistically significant,*t=3.719, 3.261, p=0.005, 0.001*. The other dosimetric parameters of B-P in the CRT plan had no statistical differences compared with the CRT+ARC plan*;*see [Table 5](#tab5){ref-type="table"} for details.

4.5. IMRT Plan versus ARC Plan {#sec4.5}
------------------------------

As shown in [Table 6](#tab6){ref-type="table"}, the minimum dose, the Conformity index, and the Homogeneity index of PTV in the IMRT pan were worse than the ARC plan, and the differences were statistically significant,*t=-5.513, -5.381, 4.768, p=0.001, 0.001, 0.001.*The other dosimetric parameters of PTV in the CRT plan had no statistical differences compared with the ARC plan.

As for OARs, the maximum dose of spinal cord, the maximum dose, and the V~50~ (%) of esophagus in the IMRT plan had no statistical differences compared with the ARC plan. The V~20~ (%) and V~30~ (%) of heart in the IMRT plan were all higher than the ARC plan, and the differences were statistically significant,*t=2.423, 2.391, p=0.038, 0.040*. The V~40~ (%), the V~45~ (%), and the mean dose of heart in the IMRT plan had no statistical differences compared with the ARC plan. The V~5~ (%) and V~10~ (%) of normal lung in the IMRT plan were lower than the ARC plan, and the differences were statistically significant,*t=-5.309, -2.697, p=0.001, 0.025*. However, The V~20~ (%) of normal lung in the IMRT plan were higher than the ARC plan, and the difference was statistically significant,*t=2.529, p=0.032.*The V~13~ (%), V~30~ (%), and the mean dose of normal lung in the IMRT plan had no statistical differences compared with the ARC plan*;*see [Table 6](#tab6){ref-type="table"} for details.

As for B-P, the V~5~ and V~10~ of B-P in the IMRT plan were lower than the ARC plan, and the differences were statistically significant,*t=-6.214, -3.055, p=0.001, 0.014*. The V~15~, V~20~, V~25~, V~30~, V~35~, and V~50~ of B-P in the IMRT plan were higher than the ARC plan, and the differences were statistically significant,*t=5.053, 8.629, 4.816, 3.998, 2.804, 3.748, p=0.001, 0.001, 0.001, 0.003, 0.021, 0.005*. The other dosimetric parameters of B-P in the IMRT plan had no statistical differences compared with the ARC plan*;*see [Table 6](#tab6){ref-type="table"} for details.

4.6. IMRT Plan versus CRT+IMRT Plan {#sec4.6}
-----------------------------------

As shown in [Table 7](#tab7){ref-type="table"}, all the dosimetric parameters of PTV in the IMRT plan had no statistical differences compared with the CRT+IMRT plan.

As for OARs, the maximum dose of spinal cord in the CRT plan was lower than IMRT plan, and the difference was statistically significant,*t=-3.257, p=0.010*. The maximum dose and the V~50~ (%) of esophagus in the IMRT plan had no statistical differences compared with the CRT+IMRT plan. The V~40~ (%) of heart in the IMRT plan was lower than the CRT+IMRT plan, and the difference was statistically significant,*t=-2.826, p=0.020*. The other dosimetric parameters of heart in the IMRT plan had no statistical differences compared with the CRT+IMRT plan. The V~5~ (%), V~10~ (%), V~13~ (%), V~20~ (%), and V~30~ (%) of normal lung in the IMRT plan were lower than the CRT+IMRT plan, and the differences were statistically significant,*t=2.325, 2.635, 4.569, 3.806, -3.661, p=0.045, 0.027, 0.001, 0.004, 0.005*. However, the V~20~ (%) of normal lung in the IMRT plan was higher than the CRT+IMRT plan, and the difference was statistically significant,*t=2.529, p=0.032.* The V~13~ (%), V~30~ (%), and the mean dose of normal lung in the IMRT plan had no statistical differences compared with the CRT+IMRT plan, see [Table 7](#tab7){ref-type="table"} for details.

As for B-P, the V~5~ and V~10~ of B-P in the IMRT plan were higher than the CRT+IMRT plan, and the differences were statistically significant,*t=4.936, 5.371, p=0.001, 0.001*. The V~25~, V~30~, V~35~, V~40~, V~45~, and V~50~ of B-P in the IMRT plan were lower than IMRT plan, and the differences were statistically significant,*t=-3.705, -4.924, -3.716, -2.322, -1.857, -2.369, p=0.005, 0.001, 0.005, 0.045, 0.046, 0.042*. The other dosimetric parameters of B-P in the IMRT plan had no statistical differences compared with the CRT+IMRT plan*;*see [Table 7](#tab7){ref-type="table"} for details.

4.7. IMRT Plan versus CRT+ARC Plan {#sec4.7}
----------------------------------

As shown in [Table 8](#tab8){ref-type="table"}, the minimum dose, the Conformity index, and the Homogeneity index of PTV in the IMRT pan were worse than the CRT+ARC plan, and the differences were statistically significant,*t=-6.509, -4.763, 6.611, p=0.001, 0.001, 0.001.*The other dosimetric parameters of PTV in the IMRT plan had no statistical differences compared with the CRT+ARC plan.

As for OARs, the maximum dose of spinal cord, the maximum dose, and the V~50~ (%) of esophagus in the IMRT plan had no statistical differences compared with the CRT+ARC plan. The V~30~ (%) of heart in the IMRT plan was lower than the CRT+ARC plan, and the difference was statistically significant,*t=-1.936, p=0.006*. The other dosimetric parameters of heart in the IMRT plan had no statistical differences compared with the CRT+ARC plan. The V~10~ (%), V~13~ (%), V~20~ (%), V~30~ (%), and mean dose of normal lung in the IMRT plan were higher than the CRT+ARC plan, and the differences were statistically significant,*t=2.635, 4.569, 3.806, -3.661, 2.153, p=0.001, 0.001, 0.001, 0.006, 0.003*. But the V~5~ of normal lung in the IMRT plan had no statistical differences compared with the CRT+ARC plan*;*see [Table 8](#tab8){ref-type="table"} for details.

As for B-P, the V~15~, V~20~, V~25~, V~30~, V~35~, and V~50~ of B-P in the IMRT plan were higher than the CRT+ARC plan, and the differences were statistically significant,*t=0.616, -0.794, -3.705, -4.924,*-3.716*, p=0.042, 0.025, 0.001, 0.001, 0.005*. The other dosimetric parameters of B-P in the IMRT plan had no statistical differences compared with the CRT+ARC plan*;*see [Table 8](#tab8){ref-type="table"} for details.

4.8. ARC Plan versus CRT+IMRT Plan {#sec4.8}
----------------------------------

As shown in [Table 9](#tab9){ref-type="table"}, the minimum dose, the median dose, the conformity index, and the homogeneity index of PTV in the ARC plan were better than the CRT+IMRT plan, and the differences were statistically significant,*t=3.861, 2.480, 8.381, -2.795, p=0.004, 0.035, 0.001, 0.021.*The other dosimetric parameters of PTV in the ARC plan had no statistical differences compared with the CRT+IMRT plan.

As for OARs, the maximum dose of spinal cord, the maximum dose and the V~50~ (%) of esophagus in the ARC plan had no statistical differences compared with the CRT+IMRT plan. The V~20~ (%) and the median dose of heart in the ARC plan were lower than the CRT+IMRT plan, and the differences were statistically significant,*t=-2.591, -2.651, p=0.029, 0.026*. The other dosimetric parameters of heart in the ARC plan had no statistical differences compared with the CRT+IMRT plan. The V~5~ (%), V~10~ (%), V~13~ (%), and V~20~ (%) of normal lung in the ARC plan were higher than the CRT+IMRT plan, and the differences were statistically significant,*t=11.829, 3.791, 4.954, 3.185, -3.761, p=0.001, 0.004, 0.001, 0.011, 0.004*. But the V~30~ (%) in the ARC plan was lower than the CRT+IMRT plan, and the difference was statistically significant,*t=-3.761, p=0.004*. The mean dose of normal lung in the ARC plan had no statistical differences compared with the CRT+IMRT plan*;*see [Table 9](#tab9){ref-type="table"} for details.

As for B-P, the V~5~ and V~10~ of B-P in the ARC plan were higher than the CRT+IMRT plan, and the differences were statistically significant,*t=10.143, 6.824, p=0.001, 0.001*. However, the V~20~, V~25~, V~30~, V~35~,V~40~, V~45~, and V~50~ of B-P in the ARC plan were lower than the CRT+IMRT plan, and the differences were statistically significant,*t=-4.684, -6.648, -5.754, -3.921, -2.397, -2.136, 10.143, p=0.001, 0.001, 0.001, 0.004, 0.040, 0.049, 0.007*. The V~15~ of B-P in the ARC plan had no statistical differences compared with the CRT+IMRT plan*;*see [Table 9](#tab9){ref-type="table"} for details.

4.9. ARC Plan versus CRT+ARC Plan {#sec4.9}
---------------------------------

As shown in [Table 10](#tab10){ref-type="table"}, the conformity index of PTV in the ARC pan was better than the CRT+ARC plan, and the difference was statistically significant,*t=3.500, p=0.007.*The other dosimetric parameters of PTV in the ARC plan had no statistical differences compared with the CRT+ARC plan.

As for OARs, the maximum dose of spinal cord in the ARC plan was lower than the CRT+ARC plan, and the difference was statistically significant,*t=-6.857, p=0.001*. The maximum dose and the V~50~ (%) of esophagus in the ARC plan had no statistical differences compared with the CRT+ARC plan. The V~20~ (%) and the V~30~ (%) of heart in the ARC plan were lower than the CRT+ARC plan, and the differences were statistically significant,*t=-2.592, -3.080, p=0.029, 0.013*. The other dosimetric parameters of heart in the ARC plan had no statistical differences compared with the CRT+ARC plan. The V~5~ (%), V~10~ (%), V~13~ (%), and V~20~ (%) of normal lung in the ARC plan were higher than the CRT+ARC plan, and the differences were statistically significant,*t=4.346, 8.832, 5.856, 6.281, p=0.002, 0.001, 0.001, 0.001*. But the V~30~ (%) in the ARC plan was lower than the CRT+ARC plan, and the difference was statistically significant,*t=-4.461, p=0.002*. The mean dose of normal lung in CRT plan had no statistical difference compared with the IMRT plan*;*see [Table 10](#tab10){ref-type="table"} for details.

As for B-P, the V~25~, V~30~, and V~35~ of B-P in the ARC plan were lower than the CRT+ARC plan, and the differences were statistically significant,*t=-6.512,-6.645, -3.973, p=0.001, 0.001, 0.003*. The other dosimetric parameters of B-P in the ARC plan had no statistical differences compared with the CRT+ARC plan*;*see [Table 10](#tab10){ref-type="table"} for details.

4.10. CRT+IMRT Plan versus CRT+ARC Plan {#sec4.10}
---------------------------------------

As shown in [Table 11](#tab11){ref-type="table"}, the minimum dose, the conformity index, and the homogeneity index of PTV in the CRT+IMRT plan were worse than the CRT+ARC plan, and the differences were statistically significant,*t=-6.053, -7.334, 5.364, p=0.001, 0.001, 0.001.*The other dosimetric parameters of PTV in the CRT+IMRT plan had no statistical differences compared with the CRT+ARC plan.

As for OARs, the maximum dose of spinal cord in the CRT+IMRT plan was higher than the CRT+ARC plan, and the difference was statistically significant,*t=3.744, p=0.005*. The dosimetric parameters of the esophagus and the heart in the CRT+IMRT plan had no statistical differences compared with the CRT+ARC plan. The V~10~ (%), V~13~ (%), V~20~ (%), and the mean dose of normal lung the CRT+IMRT plan were higher than the CRT+ARC plan, and the differences were statistically significant,*t=3.546, 3.376, 7.026, p=0.006, 0.008, 0.001*. The V~30~ (%) and the mean dose of normal lung the CRT+IMRT plan had no statistical differences compared with the CRT+ARC plan*;*see [Table 11](#tab11){ref-type="table"} for details.

As for B-P, all the dosimetric parameters of B-P in the CRT+IMRT plan had no statistical differences compared with the CRT+ARC plan*;*see [Table 11](#tab11){ref-type="table"} for details.

5. Discussion {#sec5}
=============

As shown in the above results, the conformity index of PTV in the CRT plan was worse than all the other plans, the IMRT, ARC, CRT+IMRT, and CRT+ARC plan. By the CRT plan compared with the IMRT and CRT+IMRT plan, the minimum dose of PTV was better. Nevertheless, as for PTV, the CRT plan compared with the ARC and CRT+ARC plan had no any dosimetry advantages. As for OARs, the CRT plan had dosimetry advantages in esophagus than all the other plans. The CRT plan had dosimetry advantages in the V~30~ (%) of heart than the CRT+ARC plan. But as for the other OARs, the CRT plan had no any dosimetry advantages compared with all the other plans. As for B-P, the dosimetry parameters in the CRT plan were worse than the IMRT and ARC plan, but had no statistical differences compared with the CRT+IMRT and the CRT+ARC plan.

The studies \[[@B5]--[@B8]\] about PORT in stage IIIA-N2 NSCLC patients in recent years mostly adopted the CRT technique. Though the CRT is relatively safe and stable with higher marginal dose of tumor, the dosimetry advantages of the CRT are not obvious as discussed above, perhaps due to the limitations of the technique itself. In addition, if the volume of PTV is a little larger, it maybe not meet the requirement of prescription dose and make the organ not exceeding the limit dose at the same time.

As the IMRT plan compared with all the other plans, the minimum dose of PTV in the IMRT plan was worse than the CRT plan, but the conformity index was better. The dosimetry parameters of PTV in the IMRT plan had no statistical differences compared with the CRT+IMRT plan. The minimum dose, the conformity index, and the homogeneity index of PTV in the IMRT plan were worse than the ARC plan and the CRT+ARC plan. As for OARs, except the maximum dose of esophagus, the dose of all the other OARs in the IMRT plan was lower than the CRT plan. The dose of spinal cord and heart in the IMRT plan was lower than the CRT+IMRT plan, but the dose of esophagus and normal lung in the IMRT plan was higher than the CRT+IMRT plan. The dosimetry parameters of spinal cord and esophagus in the IMRT plan had no statistical differences compared with the ARC and the CRT+ARC plan. The V~20~ (%) and V~30~ (%) of heart in the IMRT plan were higher than the ARC plan. The V~20~ (%) of normal lung in the IMRT plan was higher than the ARC plan, but the V~5~ (%) and V~10~ (%) were lower than the ARC plan. The V~30~ (%) of heart in the IMRT plan was higher than the CRT+ARC plan, but the V~10~ (%), V~15~ (%), V~20~ (%), V~30~ (%), and mean dose of normal lung in the IMRT plan were all higher than the CRT+ARC plan. As for B-P, the dosimetry parameters in the IMRT plan were all lower than the CRT plan. The V~20\~50~ of B-P in the IMRT plan were all lower than the CRT+ IMRT plan, but the V~5\~10~ were higher than the CRT+ IMRT plan. The V~15\~35~ of B-P in the IMRT plan were all higher than the ARC plan, but the V~5\~10~ were lower than the ARC plan. The V~20\~35~ of B-P in the IMRT plan were all lower than the ARC plan, but the V~15~ was higher than the ARC plan.

The studies about PORT in stage IIIA-N2 NSCLC patients in recent years which adopted the IMRT technique were not many. Abigail T Berman et al. \[[@B9]\] reported an in silico comparative analysis of passive scattering proton therapy (PSPT) and intensity modulated proton therapy (IMPT) with intensity modulated photon beam radiotherapy (IMRT) PORT and concluded that IMPT demonstrates a large decrease in dose to all OARs, while PSPT reduces the low dose lung bath and increases the volume of lung receiving high dose, and reductions are seen in dosimetric parameters predictive of radiation pneumonitis and cardiac morbidity and mortality, and this reduction may correlate with a decrease in dose-limiting toxicity and improve the therapeutic ratio. Jill S. Remick et al. \[[@B10]\] investigated the survival outcomes and early toxicity profile of PORT with proton beam therapy (PBT) versus IMRT for non-small-cell lung cancer in a cohort of 61 patients with positive microscopic margins and/or positive N2 lymph nodes and found that postoperative PBT in locally advanced NSCLC is well-tolerated and has similar excellent short-term outcomes when compared with IMRT. In the above two studies, IMRT had no dosimetry advantages compared with IMPT, PSPT, and PBT. In our study as discussed above, the IMRT had certain dosimetry advantages compared with CRT, CRT+IMRT, and CRT+ARC.

Comparing the ARC plan with all other plans, the ARC plan had dosimetry advantages in PTV than all the other plans. As for OARs, the ARC plan had dosimetry advantages in spinal cord, heart and normal lung compared with the CRT plan, but had no dosimetry advantages in esophagus. Nevertheless, when compared with the CRT+ARC plan, the ARC plan had dosimetry advantages in spinal cord, heart and V~30~ (%) of normal lung, and had no dosimetry advantages in V~5~ (%), V~10~ (%), V~13~ (%), and V~20~ (%) of normal lung. The ARC plan had dosimetry advantages in heart and V~20~ (%) of normal lung compared with the IMRT plan, but had no dosimetry advantages in V~5~ (%) and V~10~ (%) of normal lung. As well as compared with the CRT+IMRT plan, the ARC plan had dosimetry advantages in spinal cord, heart, and V~30~ (%) of normal lung and had no dosimetry advantages in V~5~ (%),V~10~ (%), V~13~ (%), and V~20~ (%) of normal lung. As for B-P, the ARC plan had dosimetry advantages compared to the CRT plan and the CRT+ARC plan. The ARC plan had no dosimetry advantages in V~5~ (%) and V~10~ (%) of B-P compared with the IMRT plan and the CRT+IMRT plan, but had dosimetry advantages in V~15\~35~ (%) of B-P compared to the IMRT plan, and had dosimetry advantages in V~20\~50~ (%) of B-P compared to the CRT+IMRT plan.

The studies about PORT in stage IIIA-N2 NSCLC patients in recent years that adopted the ARC technique were fewer. Huan-Huan Wang et al. \[[@B11]\] had evaluated the ideal timing of PORT in the management of completely resected (R0) Stage IIIA-N2 NSCLC. In their study, PORT was administered using not only CRT and IMRT, but also VMAT (ARC). Nevertheless, the study did not give detailed technique parameters and patients were not grouped according to different techniques. In our study as discussed above, the ARC plan had absolute dosimetry advantages in PTV, but had no dosimetry advantages in low dose area of normal lung and B-P.

Comparing the CRT+IMRT plan with all other plans, the CRT+IMRT plan had no dosimetry differences in PTV compared to the IMRT plan and had no dosimetry advantages in PTV compared with the ARC and CRT+ARC plan. The median dose and conformity of PTV in the CRT+IMRT were better than the CRT plan, but the minimum dose and homogeneity index PTV in the CRT+IMRT were worse than the CRT plan. As for OARs, the CRT+IMRT plan had no dosimetry advantages in esophagus compared to the CRT plan, but had dosimetry advantages in heart and normal lung compared with the CRT plan. The CRT+IMRT plan compared with the IMRT plan and ARC plan had no dosimetry advantages in spinal cord, heart, and the V~30~ (%) of normal lung, but had dosimetry advantages in the V~5~ (%), V~10~ (%), V~13~ (%), and V~20~ (%) of normal lung. The CRT+IMRT plan had no dosimetry advantages in all the OARs compared with the CRT +ARC plan. As for B-P, the CRT+IMRT plan had dosimetry advantages except the V~30~ (%) of B-P compared to the CRT plan. As for the CRT+IMRT plan compared with the IMRT and ARC plan, the CRT+IMRT plan had dosimetry advantages in low dose area of B-P and had no dosimetry advantages in high dose area of B-P. The CRT+IMRT plan had no dosimetry differences compared to the CRT +ARC plan.

There was no study about PORT in stage IIIA-N2 NSCLC patients in recent years which adopted the CRT+IMRT technique. Gerrit J. Blom et al. \[[@B12]\] compared the dosimetry characteristics of Hybrid-IMRT(CRT+IMRT) with RapidArc (ARC) in locally advanced non-small-cell lung cancer. It was challenging for 60-66Gy to deliver to large target volumes due to the need to spare OARs, so Hybrid-IMRT is currently their standard technique in locally advanced non-small-cell lung cancer. Though the target volumes in PORT patients were not very large and the prescriptions were not very high generally, the dose limits of OARs were lower than patients who had no surgery. Therefore, investigating the dosimetry characteristics of the CRT+IMRT technique in PORT patients is also necessary.

The CRT+ARC plan had dosimetry advantages in PTV compared to the CRT plan, IMRT plan, and CRT+IMRT plan, but the conformal index of PTV in the CRT+ARC plan was worse than the ARC plan. As for OARs, the CRT+ARC plan had no dosimetry advantages in spinal cord and the V~30~ (%) of heart compared with the CRT plan, but had dosimetry advantages in V~20~ (%), V~40~ (%), V~45~ (%), and mean dose of heart and normal lung. The CRT+ARC plan had dosimetry advantages in normal lung compared with the IMRT plan. CRT+ARC plan had no dosimetry advantages in spinal cord and the V~30~ (%) of normal lung compared with the ARC plan, but had dosimetry advantages in heart and V~5~ (%), V~10~ (%), V~13~ (%), and V~20~ (%) of normal lung. The CRT+ARC plan had dosimetry advantages in spinal cord and normal lung compared to the CRT+IMRT plan. As for B-P, the CRT+ARC plan had dosimetry advantages in V~25\~35~ of B-P compared to the CRT plan, and had dosimetry advantages in V~10\~15~ of B-P compared to the IMRT plan. The CRT+ARC plan had no dosimetry advantages in B-P compared with the ARC plan, and had no dosimetry differences in B-P compared with the IMRT plan.

There was also no study about PORT in stage IIIA-N2 NSCLC patients in recent years which adopted the CRT+ARC technique. John Agapito \[[@B13]\] compared the dosimetry characteristics of CRT with hybrid-VMAT (CRT+ARC) in locally advanced non-small-cell lung cancer, and concluded that the hybrid technique shows promise, but the quantity assurance implications of motion at treatment needs careful consideration. As discussed above, the CRT+ARC plan compared with the ARC plan, though conformal index of PTV was worse, the low dose area of normal lung was better. The studies by Len AM. et al. \[[@B14]\] and Schallen kamp JM. et al. \[[@B15]\] indicated that the radiation pneumonitis was related to the low dose areas of normal lung. If the low dose areas of ARC plan for a patient exceed the limits dose, a CRT+ARC plan may be a better choice.

6. Conclusion {#sec6}
=============

According to the above analysis, no plan had absolute dosimetry advantages than any other plans. In the clinic, the plans could be chosen according to their dosimetry characteristics. For example, for a patient who needs protection especially for esophagus, the CRT plan could be chosen. If a plan for a patient needs a good dosimetry distribution for PTV, the ARC plan could be chosen. Another example is that the volume of PTV is a little large and the lung of a patient needs better protection, then the CRT+ARC plan could be chosen. Of course, in the course of implementation of the above radiotherapy techniques, if modern auxiliary equipment can be incorporated with them, they can be better implemented in patients. The modern auxiliary equipment includes respiratory gate control \[[@B16], [@B17]\], CBCT image guidance technology \[[@B18]--[@B20]\], and so on. In future clinical studies, we hope to see more applications of these advanced radiotherapy techniques and radiotherapy auxiliary equipment. Moreover, detailed technical parameters can be given, and each radiotherapy technique can be grouped differently to study.
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###### 

General clinical data of patients.

  Case no.   Age (yeas)   Sex   T stage   N stage   M stage   Clinical stage    Pathological pattern     PTV volume (cc)
  ---------- ------------ ----- --------- --------- --------- ---------------- ------------------------- -----------------
  01         Female       68    2         2         0         IIIA             Adenocarcinoma            220.5
  02         Female       63    2         2         0         IIIA             Adenocarcinoma            197.0
  03         Male         64    3         2         0         IIIA             Adenocarcinoma            373.3
  04         Male         65    3         2         0         IIIA             Squamous cell carcinoma   430.8
  05         Male         65    3         2         0         IIIA             Squamous cell carcinoma   389.1
  06         Male         69    2         2         0         IIIA             Squamous cell carcinoma   293.9
  07         Male         51    2         2         0         IIIA             Squamous cell carcinoma   184.7
  08         Female       63    1b        2         0         IIIA             Adenocarcinoma            178.2
  09         Male         67    3         2         0         IIIA             Large cell carcinoma      264.0
  10         Male         62    1a        2         0         IIIA             Adenocarcinoma            367.7

###### 

Comparisons of PTV, OAR, and B-P dosimetric parameters between CRT plan and IMRT plan (cGy, $\overset{-}{x} \pm s$).

  Dosimetric parameters       CRT plan         IMRT plan        Difference       *t* value   *P* value
  --------------------------- ---------------- ---------------- ---------------- ----------- -----------
  PTV                                                                                         
   Minimum dose/cGy           4353.71±69.41    3936.34±189.77   417.37±197.05    6.698       0.001
   Maximum dose/cGy           5397.29 ±82.69   5350.08±61.15    47.21±108.72     1.373       0.203
   Median dose/cGy)           5001.56±14.33    4979.08±77.62    22.48±81.23      0.875       0.404
   Conformity index           0.69±0.05        0.80±0.04        -0.11±0.06       -5.367      0.001
   Homogeneity index          0.21±0.02        0.28±0.04        -0.00±0.03       -0.330      0.749
   V~105~ (%)                 15.11±3.64       2.92±4.38        12.19±16.34      2.359       0.043
  OAR                                                                                         
   Spinal cord Maximum dose   3214.23±285.34   2636.20±179.98   578.02±259.87    7.034       0.001
   Esophagus                                                                                  
    V~50~ (%)                 8.49±9.94        17.79±14.08      -9.30±16.53      -1.778      0.109
    Maximum dose              5110.67±113.32   5270.17±109.33   -159.50±132.28   -3.813      0.004
   Heart                                                                                      
    V~20~ (%)                 23.77±21.93      20.78±21.65      2.97±1.75        5.382       0.001
    V~30~ (%)                 11.98±12.97      9.83±10.15       2.15±3.10        2.191       0.056
    V~40~ (%)                 6.92±7.43        4.87±5.24        2.05±2.26        2.864       0.019
    V~45~ (%)                 5.15±5.48        3.59±3.84        1.55±1.73        2.832       0.020
    Mean dose                 1061.75±777.82   932.07±702.92    129.68±83.46     4.913       0.001
   Normal lung                                                                                
    V~5~ (%)                  54.24±8.06       49.59±6.17       4.64±2.27        6.456       0.001
    V~10~ (%)                 37.28±8.74       35.13±7.42       2.14±2.55        2.653       0.026
    V~13~ (%)                 33.62±7.95       30.31±6.38       3.29±2.25        4.636       0.001
    V~20~ (%)                 26.62±7.23       22.22±4.48       4.40±2.32        5.982       0.001
    V~30~ (%)                 11.59±1.64       8.63±1.47        2.95±1.38        6.771       0.001
    Mean dose                 1006.29±522.53   1040.41±147.82   -34.12±418.64    -0.258      0.802
  B-P                                                                                         
   V~5~(%)                    27.31±8.42       22.91±2.48       4.39±7.40        1.879       0.093
   V~10~(%)                   18.97±5.53       15.73±2.21       3.24±4.37        2.347       0.044
   V~15~(%)                   16.03±4.77       12.55±1.83       3.48±3.84        2.870       0.018
   V~20~(%)                   12.49±4.87       9.29±1.79        3.19±4.28        2.363       0.042
   V~25~(%)                   7.33±3.41        5.19±1.40        2.13±3.05        2.216       0.054
   V~30~(%)                   4.29±2.76        2.73±0.81        1.56±2.45        2.015       0.075
   V~35~(%)                   2.94±2.29        1.51±0.46        1.44±1.97        2.317       0.046
   V~40~(%)                   1.95±1.32        0.71±0.20        1.24±1.23        3.181       0.011
   V~45~(%)                   1.24±1.06        0.28±0.10        0.95±1.01        2.957       0.016
   V~50~(%)                   0.23±0.24        0.03±0.03        0.19±.22         2.771       0.022

###### 

Comparisons of PTV, OAR, and B-P dosimetric parameters between CRT plan and ARC plan $(cGy,{\,\,}\overset{-}{x} \pm s)$.

  Dosimetric parameters       CRT plan         ARC plan          Difference        *t*value   *P*value
  --------------------------- ---------------- ---------------- ------------------ ---------- ----------
  PTV                                                                                          
   Minimum dose/cGy           4353.71±69.41    4285.12±159.09   68.59±165.02       1.314      0.221
   Maximum dose/cGy           5397.29 ±82.69   5348.30±61.22    48.99±100.59       1.540      0.158
   Median dose/cGy)           5001.56±14.33    5025.60±6.27     -24.04±17.14       -4.433     0.002
   Conformity index           0.69±0.05        0.88±0.02        -0.19±0.04         -15.148    0.001
   Homogeneity index          0.21±0.02        0.21±0.04        -0.00±0.04         -0.330     0.749
   V~105~ (%)                 15.11±3.64       0.74±.84         14.37±16.43        2.766      0.022
  OAR                                                                                          
   Spinal cord Maximum dose   3214.23±285.34   2383.08±353.89   831.15±476.47      5.516      0.001
   Esophagus                                                                                   
    V~50~ (%)                 8.49±9.94        19.48±12.51      -10.99±8.11        -4.286     0.002
    Maximum dose              5110.67±113.32   4863.6±1253.24   -611.56±1105.668   0.651      0.531
   Heart                                                                                       
    V~20~ (%)                 23.77±21.93      13.98±13.25      3.21±16.34         3.369      0.008
    V~30~ (%)                 11.98±12.97      6.66±6.03        0.29±10.33         2.393      0.040
    V~40~ (%)                 6.92±7.43        3.79±3.21        0.04±6.23          2.295      0.047
    V~45~ (%)                 5.15±5.48        2.89±2.45        0.01±4.49          2.278      0.049
    Mean dose                 1061.75±777.82   698.58±652.93    100.58±625.75      3.129      0.012
   Normal lung                                                                                 
    V~5~ (%)                  54.24±8.06       56.06±6.17       -5.33±1.66         -1.186     0.266
    V~10~ (%)                 37.28±8.74       36.61±7.24       -1.71±3.07         0.643      0.536
    V~13~ (%)                 33.62±7.95       29.20±6.20       1.82±7.01          3.860      0.004
    V~20~ (%)                 26.62±7.23       19.49±3.34       3.59±10.68         4.551      0.001
    V~30~ (%)                 11.59±1.64       8.85±0.90        1.55±3.91          5.244      0.001
    Mean dose                 1006.29±522.53   972.39±362.74    -344.47±412.264    0.203      0.844
  B-P                                                                                          
   V~5~(%)                    27.31±8.42       26.15±3.14       -3.97±6.30         0.514      0.619
   V~10~(%)                   18.97±5.53       16.54±2.41       -0.86±5.72         1.667      0.130
   V~15~(%)                   16.03±4.77       10.97±1.80       2.28±7.82          4.121      0.003
   V~20~(%)                   12.49±4.87       6.46±1.43        3.22±8.84          4.861      0.001
   V~25~(%)                   7.33±3.41        3.72±0.93        1.64±5.58          4.142      0.003
   V~30~(%)                   4.29±2.76        2.13±0.55        0.39±3.92          2.774      0.022
   V~35~(%)                   2.94±2.29        1.22±0.29        0.18±3.27          2.532      0.032
   V~40~(%)                   1.95±1.32        0.66±0.14        0.39±2.19          3.244      0.010
   V~45~(%)                   1.24±1.06        0.25±0.04        0.24±1.74          2.999      0.015
   V~50~(%)                   0.23±0.24        0.00±0.00        0.01±0.05          3.748      0.005

###### 

Comparisons of PTV, OAR, and B-P dosimetric parameters between CRT plan and CRT+IMRT plan $(cGy,{\,\,}\overset{-}{x} \pm s)$.

  Dosimetric parameters       CRT plan         CRT+IMRT plan     Difference     *t*value   *P*value
  --------------------------- ---------------- ---------------- --------------- ---------- ----------
  PTV                                                                                       
   Minimum dose/cGy           4353.71±69.41    4051.12±183.68   302.59±62.84    4.815      0.001
   Maximum dose/cGy           5397.29 ±82.69   5373.66±103.43   23.63±50.75     0.466      0.653
   Median dose/cGy)           5001.56±14.33    5017.78±9.25     -16.22±6.23     -2.604     0.029
   Conformity index           0.69±0.05        0.80±0.03        -0.11±0.04      -7.910     0.001
   Homogeneity index          0.21±0.02        0.27±0.05        -0.06±0.06      -3.006     0.015
   V~105~ (%)                 15.11±3.64       3.48±5.16        11.63±19.11     1.924      0.086
  OAR                                                                                       
   Spinal cord Maximum dose   3214.23±285.34   3181.48±556.33   32.75±188.93    0.173      0.866
   Esophagus                                                                                
    V~50~ (%)                 8.49±9.94        14.68±13.39      -6.19±10.77     -1.817     0.103
    Maximum dose              5110.67±113.32   5205.15±96.40    -94.48±109.08   -2.739     0.023
   Heart                                                                                    
    V~20~ (%)                 23.77±21.93      20.76±21.46      3.00±3.26       2.913      0.017
    V~30~ (%)                 11.98±12.97      13.12±15.14      -1.14±2.68      -1.347     0.211
    V~40~ (%)                 6.92±7.43        5.32±5.49        1.60±2.11       2.391      0.041
    V~45~ (%)                 5.15±5.48        3.86±4.20        1.29±1.36       2.996      0.015
    Mean dose                 1061.75±777.82   983.30±742.64    78.45±83.12     2.985      0.015
   Normal lung                                                                              
    V~5~ (%)                  54.24±8.06       46.88±7.19       7.35±4.28       5.435      0.001
    V~10~ (%)                 37.28±8.74       31.74±6.64       5.54±5.24       3.342      0.009
    V~13~ (%)                 33.62±7.95       24.71±4.66       8.90±5.54       5.082      0.001
    V~20~ (%)                 26.62±7.23       17.95±2.56       8.67±5.32       5.153      0.001
    V~30~ (%)                 11.59±1.64       11.34±2.11       0.24±1.68       0.457      0.659
    Mean dose                 1006.29±522.53   1001.52±127.12   4.77±447.35     0.034      0.974
  B-P                                                                                       
   V~5~(%)                    27.31±8.42       20.49±2.71       6.83±7.07       3.053      0.014
   V~10~(%)                   18.97±5.53       14.32±2.43       4.65±3.90       3.780      0.004
   V~15~(%)                   16.03±4.77       11.92±3.92       4.11±1.13       11.481     0.001
   V~20~(%)                   12.49±4.87       10.04±3.22       2.45±1.81       4.287      0.002
   V~25~(%)                   7.33±3.41        8.32±2.76        -0.98±1.56      -1.992     0.078
   V~30~(%)                   4.29±2.76        5.76±2.33        -1.47±1.16      -3.967     0.003
   V~35~(%)                   2.94±2.29        3.27±1.80        -0.32±0.78      -1.282     0.232
   V~40~(%)                   1.95±1.32        1.72±1.46        0.24±0.24       3.209      0.011
   V~45~(%)                   1.24±1.06        0.87±1.03        0.37±0.12       9.582      0.001
   V~50~(%)                   0.23±0.24        0.06±0.06        0.17±0.20       2.730      0.023

###### 

Comparisons of PTV, OAR, and B-P dosimetric parameters between IMRT plan and ARC plan $(cGy,\overset{-}{x} \pm s)$.

  Dosimetric parameters       CRT plan         CRT+ARC plan      Difference      *t*value   *P*value
  --------------------------- ---------------- ---------------- ---------------- ---------- ----------
  PTV                                                                                        
   Minimum dose/cGy           4353.71±69.41    4305.23±114.48   48.48±127.34     1.204      0.259
   Maximum dose/cGy           5397.29 ±82.69   5328.32±58.00    68.97±101.56     2.148      0.060
   Median dose/cGy)           5001.56±14.33    5068.44±77.68    -66.88±73.16     -2.891     0.018
   Conformity index           0.69±0.05        0.86±0.02        -0.18±0.05       -12.227    0.001
   Homogeneity index          0.21±0.02        0.20±0.03        0.00±0.04        0.260      0.801
   V~105~ (%)                 15.11±3.64       3.75±9.42        11.36±19.94      1.801      0.105
  OAR                                                                                        
   Spinal cord Maximum dose   3214.23±285.34   2870.81±535.92   343.42±622.22    1.745      0.115
   Esophagus                                                                                 
    V~50~ (%)                 8.49±9.94        17.02±12.75      -8.53±9.27       -2.911     0.017
    Maximum dose              5110.67±113.32   5229.34±79.93    -118.67±125.23   -2.997     0.015
   Heart                                                                                     
    V~20~ (%)                 23.77±21.93      20.56±21.20      3.20±3.45        2.933      0.017
    V~30~ (%)                 11.98±12.97      14.39±13.89      -2.41±2.16       -3.529     0.006
    V~40~ (%)                 6.92±7.43        4.88±4.73        2.05±2.80        2.310      0.046
    V~45~ (%)                 5.15±5.48        2.94±2.42        2.21±3.18        2.196      0.056
    Mean dose                 1061.75±777.82   872.64±788.90    189.11±256.43    2.332      0.045
   Normal lung                                                                               
    V~5~ (%)                  54.24±8.06       48.77±9.22       5.47±5.55        3.114      0.012
    V~10~ (%)                 37.28±8.74       28.30±5.43       8.98±4.48        6.330      0.001
    V~13~ (%)                 33.62±7.95       22.40±4.28       11.22±5.32       6.673      0.001
    V~20~ (%)                 26.62±7.23       14.74±2.08       11.89±5.94       6.319      0.001
    V~30~ (%)                 11.59±1.64       10.36±0.81       1.23±1.56        2.494      0.034
    Mean dose                 1006.29±522.53   952.15±120.92    54.14±452.68     0.378      0.714
  B-P                                                                                        
   V~5~(%)                    27.31±8.42       25.22±12.40      2.10±14.42       0.460      0.656
   V~10~(%)                   18.97±5.53       14.86±6.45       4.11±7.20        1.806      0.104
   V~15~(%)                   16.03±4.77       10.13±4.22       5.91±5.02        3.719      0.005
   V~20~(%)                   12.49±4.87       7.99±2.65        4.50±4.37        3.261      0.010
   V~25~(%)                   7.33±3.41        6.83±1.99        0.50±2.90        0.546      0.598
   V~30~(%)                   4.29±2.76        5.33±1.80        -1.03±3.03       -1.077     0.309
   V~35~(%)                   2.94±2.29        3.42±1.89        -0.47±2.97       -0.501     0.628
   V~40~(%)                   1.95±1.32        1.58±1.71        0.37±2.10        0.560      0.589
   V~45~(%)                   1.24±1.06        0.68±1.19        0.57±1.55        1.149      0.280
   V~50~(%)                   0.23±0.24        0.12±0.33        0.12±0.39        0.933      0.375

###### 

Comparisons of PTV, OAR, and B-P dosimetric parameters between IMRT plan and ARC plan $(cGy,{\,\,}\overset{-}{x} \pm s)$.

  Dosimetric parameters       IMRT plan        ARC plan          Difference      *t*value   *P*value
  --------------------------- ---------------- ---------------- ---------------- ---------- ----------
  PTV                                                                                        
   Minimum dose/cGy           3936.34±189.77   4285.12±159.09   -348.78±200.06   -5.513     0.001
   Maximum dose/cGy           5350.08±61.15    5348.30±61.22    1.78±50.53       0.111      0.914
   Median dose/cGy)           4979.08±77.62    5025.60±6.27     -46.52±78.50     -1.874     0.094
   Conformity index           0.80±0.04        0.88±0.02        -0.08±0.05       -5.381     0.001
   Homogeneity index          0.28±0.04        0.21±0.04        0.07±0.05        4.768      0.001
   V~105~ (%)                 2.92±4.38        0.74±.84         2.18±3.80        1.812      0.103
  OAR                                                                                        
   Spinal cord Maximum dose   2636.20±179.98   2383.08±353.89   253.12±378.72    2.114      0.064
   Esophagus                                                                                 
    V~50~ (%)                 17.79±14.08      19.48±12.51      -1.69±11.39      -0.469     0.650
    Maximum dose              5270.17±109.33   4863.6±1253.24   406.55±1182.83   1.087      0.305
   Heart                                                                                     
    V~20~ (%)                 20.78±21.65      13.98±13.25      6.80±8.88        2.423      0.038
    V~30~ (%)                 9.83±10.15       6.66±6.03        3.16±4.18        2.391      0.040
    V~40~ (%)                 4.87±5.24        3.79±3.21        1.09±2.11        1.628      0.138
    V~45~ (%)                 3.59±3.84        2.89±2.45        0.70±1.44        1.530      0.160
    Mean dose                 932.07±702.92    698.58±652.93    233.48±338.59    2.181      0.057
   Normal lung                                                                               
    V~5~ (%)                  49.59±6.17       56.06±6.17       -6.47±3.86       -5.309     0.001
    V~10~ (%)                 35.13±7.42       36.61±7.24       -1.47±1.72       -2.697     0.025
    V~13~ (%)                 30.31±6.38       29.20±6.20       1.12±2.19        1.619      0.140
    V~20~ (%)                 22.22±4.48       19.49±3.34       2.73±3.41        2.529      0.032
    V~30~ (%)                 8.63±1.47        8.85±0.90        -0.22±1.52       -0.467     0.651
    Mean dose                 1040.41±147.82   972.39±362.74    68.01±283.07     0.760      0.467
  B-P                                                                                        
   V~5~(%)                    22.91±2.48       26.15±3.14       -3.22±1.64       -6.214     0.001
   V~10~(%)                   15.73±2.21       16.54±2.41       -0.81±0.83       -3.055     0.014
   V~15~(%)                   12.55±1.83       10.97±1.80       1.57±0.98        5.053      0.001
   V~20~(%)                   9.29±1.79        6.46±1.43        2.84±1.04        8.629      0.001
   V~25~(%)                   5.19±1.40        3.72±0.93        1.48±0.97        4.816      0.001
   V~30~(%)                   2.73±0.81        2.13±0.55        0.60±0.47        3.998      0.003
   V~35~(%)                   1.51±0.46        1.22±0.29        0.28±0.32        2.804      0.021
   V~40~(%)                   0.71±0.20        0.66±0.14        0.05±0.14        1.172      0.271
   V~45~(%)                   0.28±0.10        0.25±0.04        0.04±0.09        1.404      0.194
   V~50~(%)                   0.03±0.03        0.00±0.00        0.03±0.02        3.748      0.005

###### 

Comparisons of PTV, OAR, and B-P dosimetric parameters between IMRT plan and CRT+IMRT plan $(cGy,\overset{-}{x} \pm s)$.

  Dosimetric parameters       IMRT plan        CRT+IMRT plan     Difference      *t*value   *P*value
  --------------------------- ---------------- ---------------- ---------------- ---------- ----------
  PTV                                                                                        
   Minimum dose/cGy           3936.34±189.77   4051.12±183.68   -114.78±178.63   -2.032     0.073
   Maximum dose/cGy           5350.08±61.15    5373.66±103.43   -23.58±112.33    -0.664     0.523
   Median dose/cGy)           4979.08±77.62    5017.78±9.25     -38.70±79.38     -1.542     0.158
   Conformity index           0.80±0.04        0.80±0.03        0.00±0.05        0.060      0.954
   Homogeneity index          0.28±0.04        0.27±0.05        0.01±0.05        1.127      0.289
   V~105~ (%)                 2.92±4.38        3.48±5.16        -0.56±6.53       -0.271     0.792
  OAR                                                                                        
   Spinal cord Maximum dose   2636.20±179.98   3181.48±556.33   -545.27±529.43   -3.257     0.010
   Esophagus                                                                                 
    V~50~ (%)                 17.79±14.08      14.68±13.39      3.11±11.78       0.835      0.425
    Maximum dose              5270.17±109.33   5205.15±96.40    65.02±104.19     1.973      0.080
   Heart                                                                                     
    V~20~ (%)                 20.78±21.65      20.76±21.46      0.02±2.75        0.029      0.978
    V~30~ (%)                 9.83±10.15       13.12±15.14      -3.29±5.38       -1.936     0.085
    V~40~ (%)                 4.87±5.24        5.32±5.49        -0.45±0.51       -2.826     0.020
    V~45~ (%)                 3.59±3.84        3.86±4.20        -0.26±0.42       -1.993     0.077
    Mean dose                 932.07±702.92    983.30±742.64    -51.23±83.99     -1.929     0.086
   Normal lung                                                                               
    V~5~ (%)                  49.59±6.17       46.88±7.19       2.71±3.68        2.325      0.045
    V~10~ (%)                 35.13±7.42       31.74±6.64       3.39±4.07        2.635      0.027
    V~13~ (%)                 30.31±6.38       24.71±4.66       5.61±3.88        4.569      0.001
    V~20~ (%)                 22.22±4.48       17.95±2.56       4.27±3.55        3.806      0.004
    V~30~ (%)                 8.63±1.47        11.34±2.11       -2.71±2.34       -3.661     0.005
    Mean dose                 1040.41±147.82   1001.52±127.12   38.89±57.13      2.153      0.060
  B-P                                                                                        
   V~5~(%)                    22.91±2.48       20.49±2.71       2.43±1.56        4.936      0.001
   V~10~(%)                   15.73±2.21       14.32±2.43       1.42±0.83        5.371      0.001
   V~15~(%)                   12.55±1.83       11.92±3.92       0.63±3.23        0.616      0.553
   V~20~(%)                   9.29±1.79        10.04±3.22       -0.74±2.96       -0.794     0.448
   V~25~(%)                   5.19±1.40        8.32±2.76        -3.12±2.66       -3.705     0.005
   V~30~(%)                   2.73±0.81        5.76±2.33        -3.03±1.94       -4.924     0.001
   V~35~(%)                   1.51±0.46        3.27±1.80        -1.76±1.50       -3.716     0.005
   V~40~(%)                   0.71±0.20        1.72±1.46        -1.00±1.36       -2.322     0.045
   V~45~(%)                   0.28±0.10        0.87±1.03        -0.58±0.99       -1.857     0.046
   V~50~(%)                   0.03±0.03        0.06±0.06        0.03±0.03        -2.369     0.042

###### 

Comparisons of PTV, OAR, and B-P dosimetric parameters between IMRT plan and CRT+ARC plan $\left( {cGy,\overset{-}{x} \pm s} \right)$.

  Dosimetric parameters       IMRT plan        CRT+ARC plan      Difference      *t*value   *P*value
  --------------------------- ---------------- ---------------- ---------------- ---------- ----------
  PTV                                                                                        
   Minimum dose/cGy           3936.34±189.77   4305.23±114.48   -368.89±179.22   -6.509     0.001
   Maximum dose/cGy           5350.08±61.15    5328.32±58.00    21.76±62.08      1.108      0.296
   Median dose/cGy)           4979.08±77.62    5068.44±77.68    -89.36±127.30    -2.220     0.054
   Conformity index           0.80±0.04        0.86±0.02        -0.07±0.05       -4.763     0.001
   Homogeneity index          0.28±0.04        0.20±0.03        0.08±0.04        6.611      0.001
   V~105~ (%)                 2.92±4.38        3.75±9.42        0.83±11.02       -0.238     0.817
  OAR                                                                                        
   Spinal cord Maximum dose   2636.20±179.98   2870.81±535.92   -234.60±564.83   -3.257     0.222
   Esophagus                                                                                 
    V~50~ (%)                 17.79±14.08      17.02±12.75      0.76±11.38       0.835      0.836
    Maximum dose              5270.17±109.33   5229.34±79.93    40.83±113.85     1.973      0.286
   Heart                                                                                     
    V~20~ (%)                 20.78±21.65      20.56±21.20      0.22±2.86        0.029      0.810
    V~30~ (%)                 9.83±10.15       14.39±13.89      -4.56±3.99       -1.936     0.006
    V~40~ (%)                 4.87±5.24        4.88±4.73        -0.01±0.75       -2.826     0.967
    V~45~ (%)                 3.59±3.84        2.94±2.42        0.65±1.51        -1.993     0.205
    Mean dose                 932.07±702.92    872.64±788.90    59.43±263.06     -1.929     0.493
   Normal lung                                                                               
    V~5~ (%)                  49.59±6.17       48.77±9.22       0.83±5.61        2.325      0.652
    V~10~ (%)                 35.13±7.42       28.30±5.43       6.84±3.23        2.635      0.001
    V~13~ (%)                 30.31±6.38       22.40±4.28       7.92±4.03        4.569      0.001
    V~20~ (%)                 22.22±4.48       14.74±2.08       7.48±4.17        3.806      0.001
    V~30~ (%)                 8.63±1.47        10.36±0.81       -1.72±1.50       -3.661     0.006
    Mean dose                 1040.41±147.82   952.15±120.92    88.26±69.44      2.153      0.003
  B-P                                                                                        
   V~5~(%)                    22.91±2.48       25.22±12.40      -2.30±12.04      4.936      0.562
   V~10~(%)                   15.73±2.21       14.86±6.45       0.87±5.46        5.371      0.626
   V~15~(%)                   12.55±1.83       10.13±4.22       2.42±3.23        0.616      0.042
   V~20~(%)                   9.29±1.79        7.99±2.65        1.31±1.54        -0.794     0.025
   V~25~(%)                   5.19±1.40        6.83±1.99        -1.63±1.09       -3.705     0.001
   V~30~(%)                   2.73±0.81        5.33±1.80        -2.60±1.21       -4.924     0.001
   V~35~(%)                   1.51±0.46        3.42±1.89        -1.91±1.63       -3.716     0.005
   V~40~(%)                   0.71±0.20        1.58±1.71        -0.87±1.56       -2.322     0.112
   V~45~(%)                   0.28±0.10        0.68±1.19        -0.38±1.12       -1.857     0.302
   V~50~(%)                   0.03±0.03        0.12±0.33        -0.08±0.31       -2.369     0.426

###### 

Comparisons of PTV, OAR, and B-P dosimetric parameters between ARC plan and CRT+IMRT plan $\left( {cGy,\overset{-}{x} \pm s} \right)$.

  Dosimetric parameters       ARC plan         CRT+IMRT plan     Difference      *t*value   *P*value
  --------------------------- ---------------- ---------------- ---------------- ---------- ----------
  PTV                                                                                        
   Minimum dose/cGy           4285.12±159.09   4051.12±183.68   234.00±191.68    3.861      0.004
   Maximum dose/cGy           5348.30±61.22    5373.66±103.43   -25.36±122.01    -0.657     0.527
   Median dose/cGy)           5025.60±6.27     5017.78±9.25     7.82±9.97        2.480      0.035
   Conformity index           0.88±0.02        0.80±0.03        0.08±0.03        8.381      0.001
   Homogeneity index          0.21±0.04        0.27±0.05        -0.05±0.06       -2.795     0.021
   V~105~ (%)                 0.74±.84         3.48±5.16        -2.74±5.08       -1.707     0.122
  OAR                                                                                        
   Spinal cord Maximum dose   2383.08±353.89   3181.48±556.33   -798.40±303.74   -8.312     0.001
   Esophagus                                                                                 
    V~50~ (%)                 17.79±14.08      14.68±13.39      4.80±7.56        2.007      0.076
    Maximum dose              5270.17±109.33   5205.15±96.40    -341.53±120.23   -0.898     0.392
   Heart                                                                                     
    V~20~ (%)                 20.78±21.65      20.76±21.46      -6.78±8.27       -2.591     0.029
    V~30~ (%)                 9.83±10.15       13.12±15.14      -6.46±9.26       -2.205     0.055
    V~40~ (%)                 4.87±5.24        5.32±5.49        -1.54±2.34       -2.090     0.066
    V~45~ (%)                 3.59±3.84        3.86±4.20        -0.96±1.81       -1.676     0.128
    Mean dose                 932.07±702.92    983.30±742.64    -284.71±339.66   -2.651     0.026
   Normal lung                                                                               
    V~5~ (%)                  49.59±6.17       46.88±7.19       9.18±2.45        11.829     0.001
    V~10~ (%)                 35.13±7.42       31.74±6.64       4.85±4.05        3.791      0.004
    V~13~ (%)                 30.31±6.38       24.71±4.66       4.49±2.86        4.954      0.001
    V~20~ (%)                 22.22±4.48       17.95±2.56       1.54±1.52        3.185      0.011
    V~30~ (%)                 8.63±1.47        11.34±2.11       -2.49±2.09       -3.761     0.004
    Mean dose                 1040.41±147.82   1001.52±127.12   -29.12±286.09    -0.322     0.755
  B-P                                                                                        
   V~5~(%)                    26.15±3.14       20.49±2.71       5.66±1.76        10.143     0.001
   V~10~(%)                   16.54±2.41       14.32±2.43       2.23±1.03        6.824      0.001
   V~15~(%)                   10.97±1.80       11.92±3.92       -0.94±3.24       -0.920     0.382
   V~20~(%)                   6.46±1.43        10.04±3.22       -3.58±2.41       -4.684     0.001
   V~25~(%)                   3.72±0.93        8.32±2.76        -4.60±2.19       -6.648     0.001
   V~30~(%)                   2.13±0.55        5.76±2.33        -3.63±-1.99      -5.754     0.001
   V~35~(%)                   1.22±0.29        3.27±1.80        -2.05±1.65       -3.921     0.004
   V~40~(%)                   0.66±0.14        1.72±1.46        -1.05±1.39       -2.397     0.040
   V~45~(%)                   0.25±0.04        0.87±1.03        -0.62±1.02       -2.136     0.049
   V~50~(%)                   0.00±0.0         0.06±0.06        -0.05±0.05       10.143     0.007

###### 

Comparisons of PTV, OAR, and B-P dosimetric parameters between ARC plan and CRT+ARC plan $\left( {cGy,\overset{-}{x} \pm s} \right)$.

  Dosimetric parameters       ARC plan         CRT+ARC plan      Difference      *t*value   *P*value
  --------------------------- ---------------- ---------------- ---------------- ---------- ----------
  PTV                                                                                        
   Minimum dose/cGy           4285.12±159.09   4305.23±114.48   -20.11±157.12    -0.405     0.695
   Maximum dose/cGy           5348.30±61.22    5328.32±58.00    19.98±37.33      1.692      0.125
   Median dose/cGy)           5025.60±6.27     5068.44±77.68    -42.84±79.30     -1.708     0.122
   Conformity index           0.88±0.02        0.86±0.02        0.01±0.01        3.500      0.007
   Homogeneity index          0.21±0.04        0.20±0.03        0.01±0.03        0.633      0.543
   V~105~ (%)                 0.74±.84         3.75±9.42        -3.01±9.58       -0.993     0.347
  OAR                                                                                        
   Spinal cord Maximum dose   2383.08±353.89   2870.81±535.92   -487.73±224.92   -6.857     0.001
   Esophagus                                                                                 
    V~50~ (%)                 17.79±14.08      17.02±12.75      2.45±5.72        1.358      0.207
    Maximum dose              5270.17±109.33   5229.34±79.93    -365.72±383.31   -0.954     0.365
   Heart                                                                                     
    V~20~ (%)                 20.78±21.65      20.56±21.20      -6.57±8.02       -2.592     0.029
    V~30~ (%)                 9.83±10.15       14.39±13.89      -7.72±7.93       -3.080     0.013
    V~40~ (%)                 4.87±5.24        4.88±4.73        -1.09±1.58       -2.193     0.056
    V~45~ (%)                 3.59±3.84        2.94±2.42        -0.04±0.19       -0.734     0.481
    Mean dose                 932.07±702.92    872.64±788.90    -174.05±470.84   -1.169     0.272
   Normal lung                                                                               
    V~5~ (%)                  49.59±6.17       48.77±9.22       7.30±5.31        4.346      0.002
    V~10~ (%)                 35.13±7.42       28.30±5.43       8.30±2.97        8.832      0.001
    V~13~ (%)                 30.31±6.38       22.40±4.28       6.79±3.67        5.856      0.001
    V~20~ (%)                 22.22±4.48       14.74±2.08       4.75±2.39        6.281      0.001
    V~30~ (%)                 8.63±1.47        10.36±0.81       -1.50±1.06       -4.461     0.002
    Mean dose                 1040.41±147.82   952.15±120.92    20.24±91.13      0.222      0.829
  B-P                                                                                        
   V~5~(%)                    26.15±3.14       25.22±12.40      0.93±11.79       0.250      0.808
   V~10~(%)                   16.54±2.41       14.86±6.45       1.68±6.01        0.885      0.399
   V~15~(%)                   10.97±1.80       10.13±4.22       0.85±3.89        0.692      0.506
   V~20~(%)                   6.46±1.43        7.99±2.65        -1.53±2.15       -2.250     0.051
   V~25~(%)                   3.72±0.93        6.83±1.99        -3.11±1.51       -6.512     0.001
   V~30~(%)                   2.13±0.55        5.33±1.80        -3.19±1.51       -6.645     0.001
   V~35~(%)                   1.22±0.29        3.42±1.89        -2.19±1.74       -3.973     0.003
   V~40~(%)                   0.66±0.14        1.58±1.71        -0.92±1.65       -1.766     0.111
   V~45~(%)                   0.25±0.04        0.68±1.19        -0.43±1.18       -1.147     0.281
   V~50~(%)                   0.00±0.0         0.12±0.33        -0.11±0.32       -1.105     0.298

###### 

Comparisons of PTV, OAR, and B-P dosimetric parameters between CRT+IMRT plan and CRT+ARC plan $\left( {cGy,\overset{-}{x} \pm s} \right)$.

  Dosimetric parameters       CRT+IMRT plan    CRT+ARC plan      Difference      *t*value   *P*value
  --------------------------- ---------------- ---------------- ---------------- ---------- ----------
  PTV                                                                                        
   Minimum dose/cGy           4051.12±183.68   4305.23±114.48   -254.11±132.76   -6.053     0.001
   Maximum dose/cGy           5373.66±103.43   5328.32±58.00    45.34±115.42     1.242      0.246
   Median dose/cGy)           5017.78±9.25     5068.44±77.68    -50.66±74.52     -2.150     0.060
   Conformity index           0.80±0.03        0.86±0.02        0.07±0.03        -7.334     0.001
   Homogeneity index          0.27±0.05        0.20±0.03        0.06±0.03        5.364      0.001
   V~105~ (%)                 3.48±5.16        3.75±9.42        -0.27±11.52      -0.074     0.943
  OAR                                                                                        
   Spinal cord Maximum dose   3181.48±556.33   2870.81±535.92   310.67±262.39    3.744      0.005
   Esophagus                                                                                 
    V~50~ (%)                 14.68±13.39      17.02±12.75      -2.34±4.33       -1.709     0.122
    Maximum dose              5205.15±96.40    5229.34±79.93    -24.19±73.44     -1.042     0.325
   Heart                                                                                     
    V~20~ (%)                 20.76±21.46      20.56±21.20      0.20±0.53        1.178      0.269
    V~30~ (%)                 13.12±15.14      14.39±13.89      -1.27±2.18       -1.843     0.098
    V~40~ (%)                 5.32±5.49        4.88±4.73        0.45±0.88        1.617      0.140
    V~45~ (%)                 3.86±4.20        2.94±2.42        0.92±1.88        1.547      0.156
    Mean dose                 983.30±742.64    872.64±788.90    110.66±322.92    1.084      0.307
   Normal lung                                                                               
    V~5~ (%)                  46.88±7.19       48.77±9.22       -1.88±5.28       -1.127     0.289
    V~10~ (%)                 31.74±6.64       28.30±5.43       3.44±3.07        3.546      0.006
    V~13~ (%)                 24.71±4.66       22.40±4.28       2.31±2.17        3.376      0.008
    V~20~ (%)                 17.95±2.56       14.74±2.08       3.22±1.45        7.026      0.001
    V~30~ (%)                 11.34±2.11       10.36±0.81       0.99±2.04        1.528      0.161
    Mean dose                 1001.52±127.12   952.15±120.92    49.37±30.51      5.117      0.001
  B-P                                                                                        
   V~5~(%)                    20.49±2.71       25.22±12.40      -4.73±11.15      -1.341     0.213
   V~10~(%)                   14.32±2.43       14.86±6.45       -0.54±5.74       -0.300     0.771
   V~15~(%)                   11.92±3.92       10.13±4.22       1.79±4.96        1.143      0.283
   V~20~(%)                   10.04±3.22       7.99±2.65        2.05±3.37        1.923      0.087
   V~25~(%)                   8.32±2.76        6.83±1.99        1.49±2.74        1.715      0.120
   V~30~(%)                   5.76±2.33        5.33±1.80        0.43±2.47        0.553      0.594
   V~35~(%)                   3.27±1.80        3.42±1.89        -0.15±2.56       -0.186     0.856
   V~40~(%)                   1.72±1.46        1.58±1.71        0.13±2.19        0.195      0.850
   V~45~(%)                   0.87±1.03        0.68±1.19        0.19±1.57        0.393      0.703
   V~50~(%)                   0.06±0.06        0.12±0.33        -0.06±0.32       -0.553     0.594

[^1]: Academic Editor: Nikolaos Siafakas
